145,300 Shares in Amneal Pharmaceuticals, Inc. $AMRX Bought by Capula Management Ltd

Capula Management Ltd purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 145,300 shares of the company’s stock, valued at approximately $1,454,000.

Other hedge funds also recently made changes to their positions in the company. Comerica Bank increased its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Rafferty Asset Management LLC boosted its position in shares of Amneal Pharmaceuticals by 22.0% in the 2nd quarter. Rafferty Asset Management LLC now owns 16,984 shares of the company’s stock valued at $137,000 after purchasing an additional 3,066 shares during the period. Exchange Traded Concepts LLC purchased a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $31,000. SG Americas Securities LLC grew its stake in Amneal Pharmaceuticals by 3.5% during the 2nd quarter. SG Americas Securities LLC now owns 99,129 shares of the company’s stock worth $802,000 after buying an additional 3,368 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in Amneal Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 94,012 shares of the company’s stock worth $941,000 after buying an additional 4,125 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Down 2.3%

Shares of Amneal Pharmaceuticals stock opened at $11.83 on Friday. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of 51.44 and a beta of 1.35. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $15.42. The company’s 50-day simple moving average is $13.78 and its 200-day simple moving average is $12.00.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Barclays initiated coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price on the stock. Finally, Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average price target of $14.20.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.